Liver Cancer News
2013 News/Liver Cancer
Survival Rates at 1 Year Were Higher in TACE-vs Sorafenib-Treated Patients With Hepatocellular Carcinoma: Presented at ASCO Quality Care
Hepatitis C - Aging population escalates demand for liver transplantation
Liver Cancer - Painkillers May Protect Liver
Metformin may protect against hepatocellular carcinoma
Chronic HCV infection: epidemiological and clinical relevance
Suppression of HCV reduces hepatoma risk
Researchers Build on Diabetes-Liver Cancer Connection
Researchers Build on Diabetes-Liver Cancer Connection
Liver transplant survival higher among patients with NASH, HBV; lower for HCV, HCC
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma
Delcath CHEMOSAT CE Marked to Deliver High Dose Doxorubicin to Liver Cancer
Hepatitis C - Antiviral drugs cut liver cancer risk
Antiviral Therapy May Halve Risk of Liver Cancer After Chronic Hepatitis C Infection
Common Medical Screen Predicts Liver Cancer Risk in General Population
Percutaneous RFA for HCC leads to frequent recurrences, high survival rates
A novel oncogenic network specific to liver cancer initiation
Liver Cancer - A Supplement Fairy Tale
Podcast: Survival Model in Patients with HCC
Is there an opportunity for personalized medicine in HCC?
Patients With Diabetes,Chronic Hepatitis C Risk For Malignancies
Gemcitabine/oxaliplatin treatment effective in patients with advanced HCC
Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
Nordion Provides Update on Europe-Focused Phase III Clinical Trial for TheraSphere® Yttrium-90 Liver Cancer Treatment
Best Approach Controversial in Early HCC
Disparities Affect Inpatient Mortality in HCC
HBV vs HCV Infection on Viral Hepatitis-Associated HCC
Cancer leading cause of death for U.S. Hispanics, study says
Hepatitis C and B: Listen to a conversation about liver cancer
A New Liver Cancer Biomarker?
A marker detectable in the blood may be the low-cost, objective tool that clinicians
worldwide need to detect hepatocellular carcinoma.
Disparities Affect Inpatient Mortality in Liver Cancer
Liver Cancer Cells Stop Making Glucose As They Become Cancerous
NEW PERSPECTIVES IN HEPATOCELLULAR CARCINOMA
Jennerex begins Phase 2 HCC trial of JX-594
Jennerex has treated the first patient in a Phase 2 clinical trial of intravenous treatment with JX-594 for patients with advanced hepatocellular carcinoma (HCC) who have not received treatment with sorafeni.
Potentially Curative Treatment in Patients With Hepatocellular Cancer
Medscape published data on the importance of early diagnoses of HCC, and the excellent survival rate for patients who underwent curative treatments. View Full Text @ Medscape, or click here to read only the discussion/conclusion.
Survey: Surgeons Play to Strengths in Early Hepatocellular Cancer
Hepatocellular carcinoma - Brivanib Phase III Does Not Meet Overall Survival Primary Endpoint
Loss of Tiny Liver Molecule Might Lead to Liver Cancer
Combination of Tarceva, Nexavar fails to meet main goal of Phase III liver cancer study
Vitamin E may lower liver cancer risk
Sorafenib beneficial in liver cancer regardless of etiology
Dr. Bruix and colleagues note that the Sorafenib Hepatocellular Carcinoma Assessment Randomized
Protocol (SHARP) trial showed that in patients with well-preserved liver function and advanced disease, the drug improves overall survival and is safe. An Asia-Pacific trial confirmed those findings.
Meta-analysis identifies risk factors for primary liver cancers
Factors including cirrhosis, chronic HBV/HCV infection, obesity, diabetes and alcohol use were linked to an increased risk for intrahepatic cholangiocarcinoma in a recent study.
Alcoholic cirrhosis -Study doubts value of liver cancer screening
Consumption of n-3 Fatty Acids and Fish Reduces Risk of Hepatocellular Carcinoma
Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma
Mahmoud A. Khattab, Mohammed Eslam, Yousef I. Mousa, Nosa Ela-adawy, Shimaa Fathy, Mohammed Shatat,
Hesham Abd-Aalhalim, Amal Kamal, Mohammed A. Sharawe
Transforming growth factor α immunoreactivity. A study in hepatocellular carcinoma and in non-neoplastic
Vera Lucia Pannain, José Rodrigo Morais, Osmar Damasceno-Ribeiro, Venâncio Avancini-Alves
Positive Phase 2 Study Results for Tivantinib in Previously Treated Hepatocellular Carcinoma to Be Presented at ASCO
Liver Cancer Rates Continue to Rise, Vigilance Warranted
New Drug Could Be Game Changer For Sanofi
by Andrew Allen
Sanofi Aventis (SNY) is about to begin testing a drug aimed at the treatment of liver cancer. The compound that Sanofi is inventing is one that has never been seen before. It is essentially a novelty. The idea behind it is that it will starve liver cancer cells and thereby kill the cancer. The trial will begin next year and will be held in China, and perhaps in Korea as well. The compound is known as "slit-trap."
Liver cancer - Sanofi to test cancer-starving compound in China in 2013
DDW-Metformin Shows Dose-Dependent Risk Reduction of HCC in Patients With Diabetes
Radiofrequency Ablation Is Locally Curative for Hepatocellular Carcinoma
Surveillance of Patients at Risk for HCC Paltry, at 6%
by Christina Frangou
San Francisco—For patients at highest risk for hepatocellular carcinoma (HCC),
the careful surveillance that can lead to early diagnosis is simply not happening,
according to a recent study
Singal AG et al. J Gen Intern Med 2012 Jan 4 [Epub ahead of print].
Studies Illustrate Role of HCV Infection as Risk Factor for HCC
Researchers Stress Importance of Early Detection of HCV
Expert Reviews Diagnostic Imaging for HCC
Increased Sensitivity of Imaging Exams Could Help Improve Surveillance
Breakthrough in Bile Duct Cancer With Discovery of New Gene Mutations
May 14, 2012 — Scientists have made a significant breakthrough in understanding
the cause of bile duct cancer, a deadly type of liver cancer. By identifying several new genes
frequently mutated in bile duct ... > full story
Droplet Array Sheds Light On Drug-Resistant Cancer Stem Cells
ScienceDaily (May 9, 2012) —
Researchers at the Institute of Bioengineering and Nanotechnology (IBN), the
world's first bioengineering and nanotechnology research institute, have
developed a miniaturized biochip for investigating the effect of drugs on cancer
stem cells (CSCs). Published recently in Nano Today,
this new technology could boost the development of more effective cancer drugs.
Using the Droplet Array, the IBN researchers investigated the drug responses of
CSCs extracted from breast, liver and colon cancer cells. It was found that
chemotherapeutic drugs such as doxorubicin, which usually induce cell death in
liver cancer cells, demonstrated poor efficacy in liver CSCs. The CSCs from the
breast and colon tumors also showed much greater ability to survive the effects
of anti-cancer drugs.. Continue Reading...
Combination of Two Drugs Reverses Liver Tumors, Study Suggests
EASL-Brivanib Improves Time-to-Progression in Patients With HCC, but Fails to Improve Overall Survival
Family History of Liver Cancer Increases Risk of Developing the Disease
Risk of Hepatocellular Carcinoma in Diabetic Patients and Risk Reduction Associated With Anti-diabetic Therapy
Tremelimumab Shows Promise in Patients With Liver Cancer
Alpha-fetoprotein levels are prognostic after liver transplants for hepatocellular carcinoma
Commonly used diabetes drug may help to prevent primary liver cancer
New study shows liver cancer patients are less likely to die on wait list than candidates without cancer
Radio Wave Technology Adds More Days For Liver Cancer Patients
2012-New guidelines on the management of hepatocellular carcinoma (HCC)
EASL-EORTC publish joint Clinical Practice Guidelines on the management of Hepatocellular Carcinoma
PDF Download -
View the clinical practice guidelines on the management of hepatocellular carcinoma (HCC).
The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) today publish their first joint Clinical Practice Guidelines (CPGs) on the management of hepatocellular carcinoma (HCC). The EASL-EORTC guidelines define the use of
surveillance, diagnosis and therapeutic strategies recommended for patients with HCC.
HCC is the most common form of liver cancer, representing more than 90% of primary liver cancers and an increasing global health burden. It is estimated that, by 2020, the number of cases will reach 78,000 in Europe (up from 65,000 in 2008) and 27,000 in the US (up from 21,000 in 2008). Affecting 2.4 times more men than women, approximately 90% of HCCs are associated with a known underlying risk factor - the most frequent including chronic viral hepatitis (types B and C), alcohol intake and aflatoxin exposure.
Lead author Professor Josep M Llovet said: “Despite the availability of effective surveillance and treatment strategies for HCC, the proportion of patients currently receiving these interventions is suboptimal. When considered in light of HCC’s growing European and global incidence, it is critical that measures are implemented to increase access to surveillance, early diagnosis and effective treatment.”
Clinical Practice Guidelines / Issue 7 (April 2012) Management of Hepatocellular Carcinoma
Podcast:Hepatitis-Risk For Liver Cancer
Dr. Melanie Thomas, associate professor of medicine in the division of hematology/oncology and associate director of clinical investigations at Hollings Cancer Center, discusses some of the more common types and causes of
liver cancer. Dr. Thomas explains how liver cancer can often be brought on by certain conditions known to damage and stress the liver itself, such as hepatitis B and C, diabetes, obesity and excessive alcohol consumption. She stresses the importance of regular screenings for hepatitis and cirrhosis patients due to the increased risk for developing liver cancer. Dr. Thomas
concludes this podcast by discussing the high level of care patients can expect from the specialists who focus on this disease at Hollings Cancer Center.
Surgery better than chemoembolization for HCC with portal vein thrombus
NEW YORK (Reuters Health) - Patients with hepatocellular carcinoma (HCC) complicated by portal vein tumor thrombus
survive longer after resection than after transcatheter arterial chemoembolization (TACE), a retrospective study suggests.
Osteopontin as a novel marker for early hepatocellular carcinoma
2/20/2012 GastroHep.com News
The most recent issue of Hepatology identifies osteopontin as a novel marker for early hepatocellular carcinoma.
Click Here To Listen: Update On The Treatment Of Liver Cancer
Source: Cancer Care Connect
Leading experts in oncology provide up-to-date information in one-hour workshops over the telephone or online.
- Overview of Liver Cancer
- Current Standard of Care
- New Treatment Approaches
- The Role of Clinical Trials
- How Research Contributes to Treatment Options
- Controlling Symptoms and Pain
- Nutritional Concerns and Tips
- Communicating with Your Health Care Team
- Questions for Our Panel of Experts
Increased Risk Of Fatal Side Effects From 3 'Targeted' Cancer Drugs
The study looked at three drugs: sorafenib (Nexavar), sunitinib (Sutent), and pazopanib (Votrient). Sorafenib is approved to treat kidney and liver cancer, sunitinib to treat kidney cancer and gastrointestinal stromal tumor (GIST), and pazopanib to treat kidney cancer.....
Proton Therapy Treatment for Liver Cancer
Proton therapy has several advantages in treating liver cancer over traditional radiation therapy. Since the proton beam is so exact, larger dosages of radiation can be applied to the affected area, while sparing surrounding healthy tissue. Proton therapy also successfully addresses technical challenges, including liver movement during treatment when the patient breathes. Christopher Crane, M.D., Professor in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses proton therapy as well as other options available to liver cancer patients.
Hepatocellular carcinoma - Jonathan Manning, Consultant Gastroenterologist, Scottish Borders. Reviewed by Luke Koupparis, general practitioner, Bristol. Tuesday, 7 February 2012
Also See- 2010-2011 Liver Cancer News Digest